Assessment of gastrointestinal and cardiovascular risk in patients with osteoarthritis who require NSAIDs: the LOGICA study
Ángel Lanas(Hospital Clínico Universitario Lozano Blesa), José Luis Zamorano(Hospital Universitario Ramón y Cajal), Jesús Tornero(Hospital Universitario de Guadalajara)
Cited by 112
Related Papers
2016 ESC/EAS Guidelines for the Management of Dyslipidaemias
|European Heart Journal|2016|3.2k
2016 ESC/EAS Guidelines for the Management of Dyslipidaemias
|Revista Española de Cardiología (English Edition)|2017|105
Current practice in identifying and treating cardiovascular risk, with a focus on residual risk associated with atherogenic dyslipidaemia
|European Heart Journal Supplements|2016|101
A review of the evidence on reducing macrovascular risk in patients with atherogenic dyslipidaemia: A report from an expert consensus meeting on the role of fenofibrate–statin combination therapy
|Atherosclerosis Supplements|2015|84
Lipid‐lowering efficacy and safety of alirocumab in patients with or without diabetes: <scp>A</scp> sub‐analysis of <scp>ODYSSEY COMBO II</scp>
|Diabetes Obesity and Metabolism|2017|50